Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody for Non-Small Cell Lung Carcinoma (NSCLC)

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
UCLA Cancer Center, Santa Monica, CA
Non-Small Cell Lung Carcinoma (NSCLC)+2 More
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody - Drug
Eligibility
18+
All Sexes
Eligible conditions
Select

Study Summary

This study is evaluating whether a drug called atezolizumab can be used to treat lung cancer.

See full description

Eligible Conditions

  • Non-Small Cell Lung Carcinoma (NSCLC)

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody will improve 1 primary outcome and 3 secondary outcomes in patients with Non-Small Cell Lung Carcinoma (NSCLC). Measurement will happen over the course of After surgery (approximately 10 weeks).

Week 10
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Percentage of Participants With Major Pathologic Response (MPR)
Percentage of Participants With Major Pathologic Response Rates For Programmed Death Ligand 1 (PD-L1)-Positive Versus PD-L1-Negative Participants
Month 5
Percentage of Participants With Adverse Events

Trial Safety

Safety Estimate

2 of 3
This is better than 68% of similar trials

Side Effects for

Arm A (Atezo+CP)
ALOPECIA
45%
ANAEMIA
37%
NAUSEA
33%
FATIGUE
28%
ARTHRALGIA
26%
NEUROPATHY PERIPHERAL
26%
CONSTIPATION
26%
DECREASED APPETITE
25%
DYSPNOEA
22%
COUGH
21%
DIARRHOEA
21%
ASTHENIA
19%
RASH
18%
VOMITING
17%
MYALGIA
17%
NEUTROPENIA
15%
PERIPHERAL SENSORY NEUROPATHY
14%
BACK PAIN
13%
PRURITUS
13%
INSOMNIA
13%
PYREXIA
13%
THROMBOCYTOPENIA
12%
PAIN IN EXTREMITY
11%
HYPOMAGNESAEMIA
10%
PLATELET COUNT DECREASED
10%
HEADACHE
10%
CHEST PAIN
10%
URINARY TRACT INFECTION
9%
PARAESTHESIA
9%
NEUTROPHIL COUNT DECREASED
8%
HYPOTHYROIDISM
8%
NASOPHARYNGITIS
8%
DIZZINESS
7%
WEIGHT DECREASED
7%
ABDOMINAL PAIN
7%
OEDEMA PERIPHERAL
7%
PAIN
6%
ALANINE AMINOTRANSFERASE INCREASED
6%
STOMATITIS
6%
ASPARTATE AMINOTRANSFERASE INCREASED
6%
UPPER RESPIRATORY TRACT INFECTION
6%
HYPOKALAEMIA
6%
ANXIETY
6%
DRY SKIN
6%
PNEUMONIA
5%
LEUKOPENIA
5%
MALAISE
5%
WHITE BLOOD CELL COUNT DECREASED
4%
BONE PAIN
4%
DEPRESSION
4%
DYSGEUSIA
4%
HYPERTENSION
4%
EPISTAXIS
4%
HAEMOPTYSIS
4%
BRONCHITIS
4%
FEBRILE NEUTROPENIA
3%
MUCOSAL INFLAMMATION
3%
GASTROOESOPHAGEAL REFLUX DISEASE
3%
HYPONATRAEMIA
3%
MUSCLE SPASMS
3%
DYSPHONIA
3%
DRY MOUTH
3%
OROPHARYNGEAL PAIN
2%
DEHYDRATION
2%
PROTEINURIA
2%
PNEUMONITIS
2%
PULMONARY EMBOLISM
2%
MYOCARDIAL INFARCTION
1%
SEPTIC SHOCK
1%
FEMUR FRACTURE
1%
HERPES ZOSTER
1%
SEIZURE
1%
PNEUMOTHORAX
1%
EMPYEMA
1%
HIP FRACTURE
1%
ATRIAL FIBRILLATION
1%
CEREBROVASCULAR ACCIDENT
1%
GASTROINTESTINAL HAEMORRHAGE
1%
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
1%
PULMONARY OEDEMA
1%
ANAPHYLACTIC REACTION
1%
RESPIRATORY TRACT INFECTION
1%
SEPSIS
1%
INFUSION RELATED REACTION
1%
FLANK PAIN
1%
EMBOLISM
1%
DRUG HYPERSENSITIVITY
1%
DEVICE RELATED INFECTION
1%
LOWER RESPIRATORY TRACT INFECTION
1%
ISCHAEMIC STROKE
1%
ACUTE RESPIRATORY FAILURE
1%
PLEURAL EFFUSION
1%
HYPOXIA
1%
DYSPHAGIA
1%
PARTIAL SEIZURES
1%
ACUTE KIDNEY INJURY
1%
ERYTHEMA MULTIFORME
1%
INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION
0%
RESPIRATORY SYNCYTIAL VIRUS BRONCHITIS
0%
PERICARDITIS
0%
PARAINFLUENZAE VIRUS INFECTION
0%
ATRIAL FLUTTER
0%
GLOSSODYNIA
0%
OSTEOMYELITIS
0%
TROPONIN INCREASED
0%
ADENOCARCINOMA GASTRIC
0%
SOMNOLENCE
0%
HICCUPS
0%
LYMPHOEDEMA
0%
CARDIAC ARREST
0%
INFLUENZA LIKE ILLNESS
0%
NON-CARDIAC CHEST PAIN
0%
HYPERSENSITIVITY
0%
CELLULITIS
0%
HYPOPHOSPHATAEMIA
0%
ENCEPHALOPATHY
0%
INFECTIOUS PLEURAL EFFUSION
0%
HYPERGLYCAEMIA
0%
CEREBRAL ISCHAEMIA
0%
HAEMATURIA
0%
TRANSIENT ISCHAEMIC ATTACK
0%
FALL
0%
C-REACTIVE PROTEIN INCREASED
0%
HEPATIC ENZYME INCREASED
0%
GENERAL PHYSICAL HEALTH DETERIORATION
0%
INFUSION SITE EXTRAVASATION
0%
INTESTINAL HAEMORRHAGE
0%
MYELOSUPPRESSION
0%
ABDOMINAL PAIN UPPER
0%
COLITIS
0%
PANCREATITIS ACUTE
0%
INFECTION
0%
ENDOCARDITIS BACTERIAL
0%
ENTEROCOLITIS BACTERIAL
0%
GASTROENTERITIS
0%
INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE
0%
PAROTITIS
0%
STAPHYLOCOCCAL INFECTION
0%
GENERAL PHYSICAL CONDITION ABNORMAL
0%
LIPASE INCREASED
0%
METASTASES TO MENINGES
0%
MARROW HYPERPLASIA
0%
ATAXIA
0%
DELUSION
0%
RASH MACULO-PAPULAR
0%
HAEMATOMA
0%
ENCEPHALITIS
0%
DELIRIUM
0%
ADRENOCORTICAL INSUFFICIENCY ACUTE
0%
INTESTINAL ISCHAEMIA
0%
HYPOPHYSITIS
0%
BONE ABSCESS
0%
DIVERTICULITIS
0%
INFECTED SKIN ULCER
0%
PYOPNEUMOTHORAX
0%
SALMONELLOSIS
0%
HUMERUS FRACTURE
0%
COMPARTMENT SYNDROME
0%
MENINGIOMA
0%
BLADDER TRANSITIONAL CELL CARCINOMA
0%
DYSAESTHESIA
0%
SPINAL CORD COMPRESSION
0%
ALCOHOL WITHDRAWAL SYNDROME
0%
RESPIRATORY FAILURE
0%
MENTAL STATUS CHANGES
0%
GLOMERULONEPHROPATHY
0%
ACUTE RESPIRATORY DISTRESS SYNDROME
0%
BRONCHOSTENOSIS
0%
INTERSTITIAL LUNG DISEASE
0%
CARDIAC FAILURE
0%
CORONARY ARTERY DISEASE
0%
PNEUMONIA ASPIRATION
0%
PLEURISY
0%
DIABETES INSIPIDUS
0%
OPTIC NEUROPATHY
0%
ABDOMINAL PAIN LOWER
0%
ILEUS PARALYTIC
0%
INGUINAL HERNIA
0%
ANAL ABSCESS
0%
BACTERIAL INFECTION
0%
PEMPHIGOID
0%
BURSITIS INFECTIVE
0%
CHRONIC SINUSITIS
0%
HAEMORRHAGIC PNEUMONIA
0%
HEPATITIS C
0%
LARGE INTESTINE INFECTION
0%
NEUTROPENIC SEPSIS
0%
PNEUMONIA ADENOVIRAL
0%
PROSTATIC ABSCESS
0%
PNEUMONIA BACTERIAL
0%
RESPIRATORY SYNCYTIAL VIRUS INFECTION
0%
SCROTAL ABSCESS
0%
STAPHYLOCOCCAL BACTERAEMIA
0%
TOOTH ABSCESS
0%
VIRAL INFECTION
0%
STERNAL FRACTURE
0%
BLOOD LACTATE DEHYDROGENASE INCREASED
0%
FAILURE TO THRIVE
0%
MUSCULAR WEAKNESS
0%
SPINAL PAIN
0%
B-CELL LYMPHOMA
0%
VERTEBRAL FORAMINAL STENOSIS
0%
BLADDER NEOPLASM
0%
DIZZINESS POSTURAL
0%
COGNITIVE DISORDER
0%
DIABETIC VASCULAR DISORDER
0%
HEMIPARESIS
0%
EMBOLISM VENOUS
0%
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE
0%
TACHYARRHYTHMIA
0%
DIVERTICULAR PERFORATION
0%
FOOD POISONING
0%
GASTRIC HAEMORRHAGE
0%
CATHETER SITE ERYTHEMA
0%
COMPLICATION ASSOCIATED WITH DEVICE
0%
DEATH
0%
HEPATITIS
0%
ENTERITIS INFECTIOUS
0%
HEPATITIS A
0%
INFLUENZA
0%
RESPIRATORY TRACT INFECTION FUNGAL
0%
VASCULAR DEVICE INFECTION
0%
ACCIDENTAL OVERDOSE
0%
FRACTURE
0%
PROCEDURAL COMPLICATION
0%
PROCEDURAL PAIN
0%
SPINAL COMPRESSION FRACTURE
0%
WOUND COMPLICATION
0%
BLOOD PRESSURE INCREASED
0%
MUSCULOSKELETAL CHEST PAIN
0%
OSTEOLYSIS
0%
SOFT TISSUE NECROSIS
0%
TUMOUR PAIN
0%
CEREBRAL HAEMORRHAGE
0%
DEPRESSED LEVEL OF CONSCIOUSNESS
0%
FOCAL DYSCOGNITIVE SEIZURES
0%
LOSS OF CONSCIOUSNESS
0%
SYNCOPE
0%
CONFUSIONAL STATE
0%
BIPOLAR DISORDER
0%
PSYCHOTIC DISORDER
0%
SUICIDAL IDEATION
0%
PLEURITIC PAIN
0%
DEEP VEIN THROMBOSIS
0%
PERIPHERAL ARTERY THROMBOSIS
0%
PERIPHERAL VASCULAR DISORDER
0%
VENOUS THROMBOSIS LIMB
0%
VENTRICULAR TACHYCARDIA
0%
ABDOMINAL SEPSIS
0%
BACTERAEMIA
0%
KLEBSIELLA SEPSIS
0%
RIB FRACTURE
0%
TRANSAMINASES INCREASED
0%
TUMOUR PSEUDOPROGRESSION
0%
CEREBRAL INFARCTION
0%
ARTERIAL OCCLUSIVE DISEASE
0%
HEPATOMEGALY
0%
HEPATOTOXICITY
0%
HAEMORRHAGE INTRACRANIAL
0%
ADRENAL INSUFFICIENCY
0%
CLOSTRIDIUM DIFFICILE INFECTION
0%
FEBRILE INFECTION
0%
NORMOCHROMIC ANAEMIA
0%
SECONDARY ADRENOCORTICAL INSUFFICIENCY
0%
CARDIAC FAILURE CONGESTIVE
0%
AUTOIMMUNE MYOCARDITIS
0%
BONE MARROW FAILURE
0%
ACUTE MYOCARDIAL INFARCTION
0%
ATRIOVENTRICULAR BLOCK SECOND DEGREE
0%
SPONTANEOUS HAEMATOMA
0%
LEFT VENTRICULAR DYSFUNCTION
0%
PANCYTOPENIA
0%
MYOCARDIAL ISCHAEMIA
0%
COLITIS ISCHAEMIC
0%
PERICARDIAL EFFUSION
0%
FAECALOMA
0%
DUODENAL ULCER
0%
INTESTINAL INFARCTION
0%
INTESTINAL PERFORATION
0%
GASTRITIS
0%
INTESTINAL ANGINA
0%
INTESTINAL OBSTRUCTION
0%
CHOLELITHIASIS
0%
LARGE INTESTINE PERFORATION
0%
LARGE INTESTINAL HAEMORRHAGE
0%
CHOLANGITIS
0%
OESOPHAGEAL FOOD IMPACTION
0%
IRRITABLE BOWEL SYNDROME
0%
CHOLANGITIS ACUTE
0%
GASTROENTERITIS CLOSTRIDIAL
0%
HYPERCALCAEMIA
0%
POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME
0%
PRESYNCOPE
0%
METABOLIC ENCEPHALOPATHY
0%
PRERENAL FAILURE
0%
RENAL IMPAIRMENT
0%
NEPHROLITHIASIS
0%
URINARY TRACT OBSTRUCTION
0%
IMMUNE-MEDIATED PNEUMONITIS
0%
RENAL INJURY
0%
TUBULOINTERSTITIAL NEPHRITIS
0%
RENAL FAILURE
0%
DERMATITIS
0%
PULMONARY HAEMORRHAGE
0%
PULMONARY NECROSIS
0%
VERTEBROPLASTY
0%
ANEURYSM
0%
AORTIC DISSECTION
0%
HYPOTENSION
0%
ORTHOSTATIC HYPOTENSION
0%
PERIPHERAL ISCHAEMIA
0%
THROMBOSIS
0%
This histogram enumerates side effects from a completed 2020 Phase 3 trial (NCT02366143) in the Arm A (Atezo+CP) ARM group. Side effects include: ALOPECIA with 45%, ANAEMIA with 37%, NAUSEA with 33%, FATIGUE with 28%, ARTHRALGIA with 26%.

Trial Design

1 Treatment Group

Atezolizumab
1 of 1
Experimental Treatment

This trial requires 181 total participants across 1 different treatment group

This trial involves a single treatment. Atezolizumab (MPDL3280A), An Engineered Anti-PD-L1 Antibody is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Atezolizumab
Drug
Participants received two cycles of atezolizumab as neoadjuvant therapy prior to surgery. Participants who demonstrated clinical benefit were eligible to receive up to 12 months of atezolizumab.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atezolizumab
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: from baseline until 90 days after end of treatment (approximately 16.5 months overall)
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly from baseline until 90 days after end of treatment (approximately 16.5 months overall) for reporting.

Closest Location

UCLA Cancer Center - Santa Monica, CA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Pathologically documented Stage IB, II, IIIA, or selected IIIB, including T3N2 or T4 (by size criteria, not by mediastinal invasion) NSCLC
Adequate pulmonary and cardiac function
Available biopsy of primary tumor with adequate samples
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Patient Q&A Section

How many people get carcinoma, non-small-cell lung a year in the United States?

"There are probably more people getting carcinoma, non-small-cell lung than clinicians think, accounting for the greater proportions of people with the disease, and these estimations are higher than estimates previously published in the United States." - Anonymous Online Contributor

Unverified Answer

What is the average age someone gets carcinoma, non-small-cell lung?

"For the first time, we identified the age distribution of patients diagnosed with carcinoma, non-small-cell lung. We also have found that almost 85% of all carcinomas were diagnosed at a body mass index (BMI) of ≤18. Given these data, clinicians will need to be attentive when addressing age-related health concerns for their patients during their health assessment and treatment." - Anonymous Online Contributor

Unverified Answer

What are the signs of carcinoma, non-small-cell lung?

"Signs of C&NSCLC include weight loss, coughing up blood, and shortness of breath. Other symptoms may include coughing up blood, and chest pain and shortness of breath.\n" - Anonymous Online Contributor

Unverified Answer

What causes carcinoma, non-small-cell lung?

"Carcinoma of the lung is strongly associated with smoking, a history of bronchiectasis and unexplained death of a first-degree relative. Carcinoma of the large airways is strongly associated with the presence of a family history of lung cancer, male sex, smoking and bronchiectasis." - Anonymous Online Contributor

Unverified Answer

Can carcinoma, non-small-cell lung be cured?

"It is conceivable that a cure will be found for NSCLC, but it would likely have to involve one of the available targeted therapies and only a small minority of patients." - Anonymous Online Contributor

Unverified Answer

What is carcinoma, non-small-cell lung?

"Non-small-cell [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) (NSCLC) is the most lethal form of cancer among Caucasians, accounting for about 25% of lung cancer in the US population. Lung cancer appears to be a product of multiple etiologies, including genetic predisposition, tobacco exposure, diet, and environmental factors. Smoking is a predominant environmental risk factor for lung cancer in both men and women." - Anonymous Online Contributor

Unverified Answer

What are common treatments for carcinoma, non-small-cell lung?

"The most common treatment for the cancer is surgery. When the disease is in the local region, surgery is a definitive therapy; if it moves the disease into another location, chemotherapy is the treatment of choice for the cancer. The disease spreads to distant and other sites of the body, then radiation therapy is the therapy of choice. Radiation therapy is also a way of looking after the cancer." - Anonymous Online Contributor

Unverified Answer

What is the survival rate for carcinoma, non-small-cell lung?

"The 3-year survival rate for non-small-cell lung cancer is 27.2±4.5%, and the 5-year survival rate is 15.6±6.0%. Survival rates based on the stage of spread of disease at the time of diagnosis are as follows: stage I and 2, 31.8% after 3 years; stage III and IV, 14.8% after 3 years." - Anonymous Online Contributor

Unverified Answer

What are the chances of developing carcinoma, non-small-cell lung?

"The risk of developing malignant diseases is markedly increased among subjects presenting to a ENT-Head and Neck Surgery Unit with nasal polyp or adenoid hypertrophy." - Anonymous Online Contributor

Unverified Answer

How does atezolizumab (mpdl3280a), an engineered anti-pd-l1 antibody work?

"Atelezolizumab, a mutant anti-PD-1 antibody, may represent a favorable treatment option for patients with a variety of NSCLC, with many patients having only mild symptoms." - Anonymous Online Contributor

Unverified Answer

Who should consider clinical trials for carcinoma, non-small-cell lung?

"The overall impact on survival of patients eligible for clinical trials for carcinoma, non-small-cell lung was not impacted by the fact study results were published, although study completion was associated with improved survival (hazard ratio <1). Clinical trials for cancer, especially lung cancer, deserve to be funded for the improvement that treatment of cancer trials could provide to millions of patients." - Anonymous Online Contributor

Unverified Answer

What does atezolizumab (mpdl3280a), an engineered anti-pd-l1 antibody usually treat?

"For these indications to be considered, the patients enrolled in these studies (both PD-L1 negative and PD-L1-expressing), and the indications are limited rather than the overall results. The following results have shown the PD-1/PD-L1 checkpoint as a target of immune response after the activation of T and B cells." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Non-Small Cell Lung Carcinoma (NSCLC) by sharing your contact details with the study coordinator.